Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal

Cancer ◽  
2013 ◽  
Vol 119 (21) ◽  
pp. 3769-3775 ◽  
Author(s):  
Cathy Eng ◽  
George J. Chang ◽  
Y. Nancy You ◽  
Prajnan Das ◽  
Yan Xing ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Anal Canal ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Locally Advanced ◽  
Long Term Results ◽  
Advanced Squamous Cell Carcinoma

A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal

2019 ◽  
Vol 18 (4) ◽  
pp. 301-306
Author(s):  
Cathy Eng ◽  
Alexandre A. Jácome ◽  
Prajnan Das ◽  
George J. Chang ◽  
Miguel Rodriguez-Bigas ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Anal Canal ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Squamous Cell ◽  
Phase Ii Study ◽  
Locally Advanced ◽  
Advanced Squamous Cell Carcinoma ◽  
Concurrent Radiotherapy

scholarly journals Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma

2020 ◽  
Vol 62 (1) ◽  
pp. 142-148
Author(s):  
Masanori Ochi ◽  
Yuji Murakami ◽  
Ikuno Nishibuchi ◽  
Katsumaro Kubo ◽  
Nobuki Imano ◽  
...  
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Adverse Events ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Locally Advanced ◽  
Long Term Results ◽  
Definitive Chemoradiotherapy

Abstract Purpose The present study aimed to evaluate the long-term results of definitive chemoradiotherapy (CRT) for unresectable locally advanced esophageal squamous cell carcinoma (LA-ESCC). Materials and methods We analyzed eighty patients with unresectable LA-ESCC, who underwent definitive CRT between 2001 and 2014. The 5-year overall survival (OS), cause-specific survival (CSS), and progression-free survival (PFS) rates were calculated, and we investigated the prognostic factors and adverse events. Results The median age was 66 years (range, 41–83 years). Histologically, all patients had squamous cell carcinoma. The most common tumor site was the middle thoracic esophagus in 43 (54%) patients. According to the eighth edition of the Union for International Cancer Control TNM classification, sixty-six patients (83%) had T4 disease, 59 (74%) had regional lymph node (LN) metastases, and 35 (44%) had distant LN metastases beyond the regional LN (M1 LYM) disease. Forty-five (56%) and 35 (44%) patients belong to clinical stages IVA and IVB, respectively. The median follow-up period for survivors was 86 months. The 5-year OS, CSS, and PFS rates were 20.2%, 25.7%, and 18.4%, respectively. On univariate analysis, only the performance status score was significantly associated with better overall survival (p = 0.026). Grade 3 or higher late adverse events were observed in 12 (15%) patients, and these included cardiopulmonary adverse events in 6 (8%) patients. Treatment-related death occurred in 3 (4%) patients. Conclusion We showed the long-term results of definitive CRT for unresectable LA-ESCC. The survivals are still poor and new treatment strategies need to be developed.

Long-term survival after chemoradiotherapy for locally advanced squamous cell carcinoma of the esophagus

1989 ◽  
Vol 17 (1) ◽  
pp. 15-19 ◽  
Author(s):  
David J. Adelstein ◽  
Vishwa M. Sharan ◽  
Norman J. Snow ◽  
Susan G. Carter ◽  
Terrence P. Horrigan ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Locally Advanced ◽  
Advanced Squamous Cell Carcinoma ◽  
Term Survival ◽  
Carcinoma Of The Esophagus ◽  
Long Term Survival
Sign in / Sign up

Export Citation Format

Share Document